CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Ledipasvir / Sofosbuvir

Last Updated: September 15, 2014
Result type: Reports
Project Number: SR0395
Product Line: Common Drug Review

Generic Name: Ledipasvir / Sofosbuvir

Brand Name: Harvoni

Manufacturer: Gilead Sciences Canada Inc.

Indications: Hepatitis C, chronic

Submission Type: Pre-NOC

Project Status: Complete

Date Recommendation Issued: March 18, 2015

Recommendation Type: List with criteria/condition